Clinical Trial Update: 52-week Open Label Safety-Tolerability Study [Phase 3]

View source ↗

Summary

LB Pharmaceuticals Inc. announced a 52-week open-label safety and tolerability study in schizophrenia patients (Phase 3), which is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• LB Pharmaceuticals investigational product

Snippet

Sponsor: LB Pharmaceuticals Inc. | Conditions: Schizophrenia | Phase 3 | Status: NOT_YET_RECRUITING